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TAKE HOME MESSAGE 1 
An interdisciplinary model of care for COPD in primary care involving smoking cessation 2 
support, home medicines review, and home-based pulmonary rehabilitation did not 3 


























We evaluated the effectiveness of an interdisciplinary, primary care-based model of care for COPD. 2 
A cluster randomised controlled trial was conducted in 43 general practices in Australia.  Adults with 3 
a history of smoking and/or COPD, aged ≥40 years with ≥2 clinic visits in the previous year were 4 
enrolled following spirometric confirmation of COPD. The model of care comprised smoking 5 
cessation support, home medicines review (HMR), and home-based pulmonary rehabilitation 6 
(HomeBase). Main outcomes included changes in St George’s Respiratory Questionnaire (SGRQ) 7 
score, COPD Assessment Test (CAT), dyspnoea, smoking abstinence and lung function at six and 12 8 
months. 9 
We identified 272 participants with COPD (157 intervention, 115 usual care); 49/157 (31%) 10 
completed both HMR and HomeBase. Intention-to-treat analysis showed no statistically significant 11 
difference in change in SGRQ at six months (adjusted between group difference 2.45 favouring 12 
intervention, 95%CI – 0.89 to 5.79). Per protocol analyses showed clinically and statistically 13 
significant improvements in SGRQ in those receiving the full intervention compared to usual care 14 
(difference 5.22, 0.19 to 10.25). No statistically significant differences were observed in change in 15 
CAT, dyspnoea, smoking abstinence or lung function. 16 
No significant evidence was found for the effectiveness of this interdisciplinary model of care for 17 















INTRODUCTION  1 
Chronic obstructive pulmonary disease (COPD) is a major public health problem. Symptoms and 2 
complications can greatly impair patients’ ability to perform activities of daily living and compromise 3 
quality of life. 4 
Management of COPD involves multiple health professionals for delivery of both pharmacological 5 
and non-pharmacological interventions for optimal outcomes. The roles of the general practitioner 6 
(GP) and other healthcare professionals in the management of COPD are important. 1 There is a trend 7 
towards an interdisciplinary approach to COPD management whereby team members from different 8 
disciplines work collaboratively, with a common aim, to set goals, make decisions and share resources 9 
and responsibilities.2 The team of health professionals from different disciplines, work together with 10 
the patient, undertakes assessment, diagnosis, intervention, goal-setting and the development of a care 11 
plan.3  Integrated disease management (IDM) requires multidisciplinary input and may be further 12 
enhanced with an interdisciplinary approach. Integrated disease management is ‘a group of coherent 13 
interventions designed to prevent or manage one or more chronic conditions using a systematic, 14 
multidisciplinary approach and potentially employing multiple treatment modalities.’ 4 A recent 15 
Cochrane review of multi-component, multi-professional IDM programs for COPD showed positive 16 
effects on disease-specific quality of life, exercise capacity, hospital admissions and length of hospital 17 
stay, but not on dyspnoea or lung function.5  Additionally, IDM programs have demonstrated positive 18 
effects on level of follow-up, pulmonary rehabilitation attendance, self-reported daily activity and 19 
disease knowledge.6, 7  However, recent multi-professional interventions for COPD management in 20 
primary care have shown no additional benefit beyond usual care on health-related quality of life 21 
(HRQoL).6, 8, 9  22 
Underutilisation of spirometry for diagnosis of COPD, sub-optimal pharmacological treatment, and 23 
low referral rates for pulmonary rehabilitation are common challenges in COPD management.10-13 24 
Smoking cessation remains crucial in COPD prevention and management, with up to 50% of smokers 25 
developing clinically significant COPD.14 Medication adherence and incorrect inhaler technique are 26 
known issues in the COPD population.15, 16 Pharmacist-led interventions in the community setting, 27 
involving medication review and patient education, have shown positive impact on inhaler technique 28 
and medication adherence.17, 18 The home medicines review (HMR) service is currently a government 29 
funded service in Australia for patients with an identifiable clinical need, at risk of medication 30 
misadventure and/or on multiple medications, including inhaler devices. Although benefits for 31 
pulmonary rehabilitation in COPD management are well established, access and completion of these 32 
programs remain low internationally.19-21 Home-based pulmonary rehabilitation programs have been 33 
evaluated and shown to provide similar outcomes to conventional centre-based rehabilitation.22  34 
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Novel models of care aimed at improving smoking cessation, COPD diagnosis, symptom control, and 1 
exacerbation prevention through interdisciplinary interventions may enhance quality of life.  Multi-2 
professional programs for COPD in primary care to date have not had explicit regard to the interaction 3 
among health professionals delivering smoking cessation support, HMRs and home-based pulmonary 4 
rehabilitation. We designed an interdisciplinary consumer-centred intervention where GPs, clinic 5 
staff, pharmacists and physiotherapists worked collaboratively, with a common purpose, to set goals, 6 
make decisions and share resources and responsibilities in the delivery of care. 7 
 8 
Aim 9 
The primary aim was to implement an interdisciplinary model of care (RADICALS – Review of 10 
Airway Dysfunction and Interdisciplinary Community-based care of Adult Long-term Smokers) in 11 
Australian primary care and evaluate its effectiveness on HRQoL at six months.  12 
We hypothesised that a primary care-based interdisciplinary team comprising the patient’s GP, clinic 13 
staff, pharmacist and physiotherapist delivering a model of care involving smoking cessation support, 14 
HMR and home-based pulmonary rehabilitation, would improve COPD-related HRQoL compared to 15 
usual care at six months.   16 
Secondary objectives were to determine the uptake of this novel model of care, improve the diagnosis 17 
of COPD in those at risk in primary care, assist smokers to quit, and improve symptoms, psychosocial 18 




We carried out a two-arm, cluster randomised controlled trial. Cluster randomisation minimises the 
risk of contamination across intervention and usual care groups. The detailed protocol of the trial and 
baseline cohort characteristics are available elsewhere.13, 23 This paper focuses on the effectiveness of 
RADICALS on primary and secondary outcomes at six and 12 months. The trial was registered with 
the Australia and New Zealand Clinical Trials Registry (ACTRN12614001155684).  
 2 
Clinic recruitment and randomisation 3 
In brief, group or solo GP clinics with at least 1000 patients on their databases were approached 4 
directly or with assistance from primary care organisations.  After obtaining signed agreement, clinics 5 
were block randomised (block sizes of four and six) to usual care or intervention arms using an 6 
externally managed web-based randomisation program.  Clinics were notified of their allocation. A 7 
baseline survey was completed by clinics to provide basic data, including details related to practice 8 
staff, availability of spirometers and staff training undertaken previously.  9 
 10 
Patient selection and data collection 11 
Trained research assistants (RAs) at each clinic identified potential participants by searching patient 12 
databases and contacting them via mail or telephone.  Patients were eligible if they were ≥40 years 13 
old, had ≥2 clinic visits during the previous year, and self-reported being a current/ex-smoker (≥10 14 
pack year smoking history) or those who had a documented diagnosis of COPD on clinic records or 15 
were being treated with COPD-specific medications. 16 
Participants attended a baseline interview at their clinic after providing written consent. Data 17 
collection was undertaken, and case-finding used the hand-held COPD-6® device (Vitalograph, Ennis, 18 
Ireland).24 Those with forced expiratory volume in 1 second (FEV1)/forced expiratory volume in 6 19 
seconds (FEV6) <0.7525 were referred for spirometry (Easy on-PC spirometers; ndd Medizintechnik 20 
AG, Zürich, Switzerland).  Spirometry was performed according to American Thoracic 21 
Society/European Respiratory Society guidelines.26 A post-bronchodilator FEV1/forced vital capacity 22 
(FVC) <0.7 suggested COPD.27 Recent spirometry undertaken outside the trial was assessed, if 23 
accessible.  An algorithm guided RAs in establishing a diagnosis of COPD (available from authors). 24 
Uncertain cases were interpreted by a respiratory scientist and/or respiratory physician.  Spirometry 25 
results, modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) scores were 26 
communicated to each participant’s GP/clinic staff for review and confirmation of diagnosis with the 27 
patient. Only those participants diagnosed as having COPD were included in the primary 28 
effectiveness analysis. 29 
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Usual care 1 
GPs in usual care practices continued to provide routine care to their patients.  Copies of the COPD-X 2 
Plan28 and the Smoking Cessation guide29 were provided to clinic staff.  Spirometry results and 3 
interpretation were made available for GPs to review. Participants were given the Lung Foundation 4 
Australia booklet ‘Better Living with Chronic Obstructive Pulmonary Disease – A Patient Guide’.30 5 
 6 
Intervention 7 
The RADICALS model of care was underpinned by Australian COPD-X guidelines.27 8 
In addition to usual care, GPs and other staff from intervention group practices were offered training 9 
on spirometry and the COPD-X guidelines 28, and a smoking cessation guide.29  10 
The RADICALS model of care comprised the following: 11 
Individualised smoking cessation support was provided to smokers using QUIT resources and guided 12 
by a treatment algorithm.31 This consisted of brief counselling and Quitline referral provided by RAs 13 
during baseline interview to all smokers in the intervention arm, regardless of COPD diagnosis.  14 
Over-the-counter and/or prescription medications for smoking cessation were also recommended, if 15 
appropriate. 16 
The home medicines review (HMR)32 was performed by an accredited consultant pharmacist and 17 
consisted of an interview with participants in their homes (approximately 1.5 hours). The interview 18 
allowed the pharmacist to assess medication use and participants’ knowledge about their medications 19 
(including inhaler use and technique), provide education focusing on medication use, and further 20 
individualised smoking cessation support, if relevant.  A report was subsequently generated by the 21 
pharmacist and forwarded to the participant’s GP outlining recommendations for optimising 22 
medication use, especially for COPD.  23 
The eight-week home-based pulmonary rehabilitation (HomeBase) program22, delivered by a 24 
specifically trained physiotherapist, consisted of one home visit and weekly follow-up telephone calls.  25 
Home-based aerobic and resistance exercise training was individually prescribed.  Telephone calls 26 
employed motivational interviewing principles to achieve disease-specific self-management training 27 
and exercise progression.  28 
The model of care was coordinated by the RA at each site under the supervision of each participant’s 29 
GP and clinic staff. Consenting patients were referred by the GP, at their discretion, to HomeBase and 30 
HMR.  Following real-world practice, normal processes of spirometry results review and patient 31 




Participants were followed at six and 12 months after baseline by RAs blinded to clinic and group 2 
allocation.  Follow-ups (telephone and/or face-to-face) involved completion of a structured 3 
questionnaire with outcomes of interest, post-bronchodilator spirometry testing and exhaled carbon 4 
monoxide (eCO) testing in smokers (if self-reported not smoking in the previous seven days).   5 
 6 
Outcomes and measurements 7 
The primary outcome was change in the overall HRQoL, measured using St George’s Respiratory 8 
Questionnaire (SGRQ)33 score, at six months from baseline. 9 
Secondary outcomes measured in participants at six and 12 months from baseline included changes 10 
in: (1)SGRQ score33 (at 12 months); (2) CAT score34; (3) mMRC grade35, 36; (4) Lung function 11 
(FEV1 %predicted)37; (5) Hospital Anxiety and Depression Scale (HADS) score38, 39; (6) Heaviness of 12 
Smoking Index (HSI) score40; (7) Proportions of COPD participants with biochemically verified 13 
seven-day point prevalence smoking abstinence – eCO levels were measured using a handheld piCO 14 
Smokerlyzer (Bedfont Scientific, Maidstone, Kent, UK) to confirm self-report of seven-day point 15 
prevalence abstinence (a participant with CO level ≤6 parts per million (ppm) was considered 16 
abstinent; missing data for smoking-related outcomes were treated in accordance with the Russell 17 
standard41, whereby a smoker lost to follow-up was considered to have continued to smoke). 18 
Process outcomes including the uptake of the HMR and HomeBase by GPs and participants, and 19 
inhaler-related issues identified during HMR, were measured by reviewing participant logs and notes 20 
recorded by the HMR pharmacist and HomeBase physiotherapists delivering these services.  21 
Description of each outcome measure is included in the published study protocol.23 22 
 23 
Sample size 24 
Change in SGRQ score at six months from baseline was the primary effectiveness endpoint. A 25 
difference of at least four points in SGRQ between treatment arms was considered clinically 26 
significant.33 Assuming a standard deviation (SD) of 10 points in SGRQ, 99 participants per group 27 
(80% power, α=0.05) were needed to detect this.  The required sample was 108 per arm (intra-class 28 
correlation=0.0142, cluster size=10).  At least 28 primary care practices need to be recruited and 14 29 
each randomised to intervention and usual care arms. Further details have been previously 30 




Statistical analysis  1 
Analyses were conducted in accordance with a predefined analysis plan.23 Baseline characteristics of 2 
the intervention and control groups were summarised according to data type and distribution.  3 
Outcomes were assessed at the participant level. All regression analyses were adjusted for clustering, 4 
age, education, income, current smoking status and prior COPD diagnosis. The effectiveness analysis 5 
was according to an intention-to-treat principle. Mean change in SGRQ score at six months in each 6 
treatment group was estimated.  Differences between groups and the corresponding 95% confidence 7 
intervals (CI) were determined.  Multivariable analysis was performed using multiple linear 8 
regression, adjusting for baseline imbalances and confounders.  Multiple imputation was generated for 9 
missing data based on the assumption that data were from a multivariate normal distribution and were 10 
missing at random.  The regression method was used for imputation with 10 imputed datasets used for 11 
each variable.  12 
Per-protocol analyses (pre-defined) were also conducted to determine effectiveness within 13 
participants completing the intervention as intended.  Completion of HomeBase was defined as 14 
completion of a minimum of 70% of total sessions (i.e. at least six out of eight sessions in the 15 
program).22 Completion of HMR was defined as having been present at a pre-booked appointment and 16 
participating in an interview with the consultant pharmacist.  Therefore, intervention group 17 
participants were categorised according to their degree of completeness: ‘full intervention’ 18 
(Completion of both HMR and HomeBase), ‘partial intervention’ (HMR only, HomeBase only, 19 
partial HomeBase only, or HMR and partial HomeBase) or ‘no intervention’. Baseline participant 20 
characteristics were compared between (1) those who completed the full intervention and those who 21 
did not; and (2) those who completed the trial and those who were lost to follow-up. Differences in 22 
baseline clinic characteristics were determined for those clinics with at least one participant 23 
completing the full intervention and those clinics with no full intervention completers. 24 
All analyses were performed using Statistical Package for Social Sciences (SPSS) (version 24.0; IBM, 25 










A total of 43 clinics were randomised to intervention (n=21) or usual care (n=22); two clinics 2 
randomised to the usual care arm withdrew before recruiting any participants (Figure 1).  3 
Characteristics of clinics have been previously described.13 Between February 2016 and April 2017, a 4 
total of 1050 participants were recruited (618 from intervention clinics and 432 from usual care 5 
clinics), of whom 272 were confirmed to have COPD (157 from intervention clinics and 115 from 6 
usual care clinics). At baseline, the groups appeared similar, although intervention group participants 7 
were older and more likely to have a trade rather than university education, but less likely to be 8 
current smokers than the usual care group (Table 1). 9 
The drop-out rates at 12 month follow-up were similar (intervention group 44/157 [28%] compared to 10 
38/115 [33%] in usual care, p=0.45). Participants who completed the 12 month follow-up were older, 11 
more likely to be in a relationship, not living independently and had better lung function (i.e. higher 12 
FEV1 %predicted) compared to those who dropped out (Supplementary file). 13 
 14 
Table 1: Baseline demographic and clinical characteristics 15 
Characteristic 
Usual Care (n=115, 16 
clinics) 
Intervention (n=157, 19 
clinics) 
Age, mean (SD) 61.7 (10.1) 66.6 (10.8) 
Gender, male 72 (62.6%) 95 (60.5%) 
Born in Australiaa 86 (74.8%) 114 (74.0%) 
Mainly speak English at home 113 (98.3%) 154 (98.1%) 
Educationa   
   No formal schooling/up to primary 
school/primary school 4 (3.5%) 14 (9.1%) 
   High school 63 (54.8%) 68 (44.2%) 
   Technical/further education 22 (19.1%) 51 (33.1%) 
   University education/postgraduate 26 (22.6%) 21 (13.6%) 
Employment statusa   
   Employed-full/part-time/casual 25 (22.3%) 51 (32.5%) 
   Retired/pensioner 68 (60.7%) 84 (53.5%) 
   Unemployed/home duties/student/unable to 
work/disabled 19 (17.0%) 22 (14.0%) 
Marital statusa   
   Married/de-facto/engaged 53 (46.1%) 69 (44.8%) 
   Separated/divorced/widowed/never 
married/single 61 (53.0%) 85 (55.2%) 
   Undisclosed 1 (0.9%) 0 (0.0%) 
Current living arrangementsa   
   With family/friends/spouse/partner 76 (66.1%) 97 (63.0%) 
   Alone at home 36 (31.3%) 51 (33.1%) 
   Shared accommodation/community 
housing/refuge accommodation/residential 
facility/residential aged care facility 3 (2.6%) 6 (3.9%) 
Average annual household incomeb   
11 
 
   <AUD $30,000 45 (40.2%) 74 (49.7%) 
   AUD $30,000-$59,999 25 (22.3%) 32 (21.5%) 
   AUD $60,000 or more 18 (16.1%) 31 (20.8%) 
   Did not want to disclose 24 (21.4%) 12 (8.1%) 
Previously managed as having COPD 56 (48.7%) 74 (47.1%) 
Currently smoking 82 (71.3%) 84 (53.5%) 
Heaviness of Smoking Index scorec   
   Low nicotine dependence (score 0-2) 24 (29.3%) 21 (26.3%) 
   Moderate nicotine dependence (score 3-4) 46 (56.1%) 44 (55.0%) 
   High nicotine dependence (score 5-6) 12 (14.6%) 27 (16.7%) 
Post-bronchodilator FEV1 %predicted, mean 
(SD)a 70.8 (19.3) 69.0 (20.5) 
Post-bronchodilator FEV1 / FVC, mean (SD)a 0.57 (0.10) 0.57 (0.13) 
Disease severity a,d   
   Mild 82 (71.9%) 108 (69.7%) 
   Moderate 26 (22.8%) 30 (19.4%) 
   Severe 6 (5.3%) 17 (11.0%) 
mMRC dyspnoea gradee   
   Grade 0 39 (34.2%) 37 (23.6%) 
   Grade 1 42 (36.8%) 70 (44.6%) 
   Grade 2 22 (19.3%) 26 (16.6%) 
   Grade 3 10 (8.8%) 21 (13.4%) 
   Grade 4 1 (0.9%) 3 (1.9%) 
amissing data for 3 participants 
bmissing data for 11 participants; Australian annual pension rate for singles is ~$24,000 
cmissing data for 4 participants 
dseverity of COPD based on COPD-X Plan; FEV1 % predicted values (60-80% predicted = mild, 40-59% 
predicted = moderate, <40% predicted = severe)28; 80 participants had FEV1 % values>80% but had characteristic 
symptoms of mild COPD 
emissing data for 1 participant 
 
COPD = Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced 




Primary outcome 3 
SGRQ scores improved in both groups between baseline and six months, however only the change in 4 
SGRQ score within the intervention group was statistically significant (3.07; 95%CI 0.73 to 5.42) 5 
(Table 2).  Difference in SGRQ score changes between groups was not statistically significant 6 
(adjusted mean difference 2.45 favouring intervention, 95%CI -0.89 to 5.79) at six months (Table 2). 7 
Multiple imputation analyses performed for missing SGRQ data showed similar results 8 
(Supplementary Table 1). No statistically significant differences in proportions of participants 9 
achieving the minimum clinically important difference (MCID) in SGRQ of four or more were 10 




Secondary outcomes 1 
Six-month outcomes 2 
Changes in CAT and lung function (FEV1% predicted) from baseline at six months between groups 3 
were not statistically significant (Table 3). There were no differences in HSI scores (median 3 [IQR 2-4 
4] in both groups, p=0.62) and proportion of smokers with biochemically-verified seven-day point 5 
prevalence smoking abstinence (intervention: 6/84 [7.1%]; usual care: 3/82 [3.7%]; p=0.50) between 6 
groups at six months. Multiple imputation analyses performed for missing CAT and FEV1%predicted 7 
data showed similar results (Supplementary Table 1). Proportions of participants who showed 8 
improvements (from baseline) in HADS anxiety/depression scores and mMRC grades were not 9 
significantly different between groups (Table 3). 10 
 11 
12-month outcomes 12 
No statistically significant differences between groups in change in SGRQ, CAT, proportions of 13 
participants achieving SGRQ MCID (data not shown), and those showing improvements (from 14 
baseline) in HADS anxiety/depression scores and mMRC grades (Table 2 and 3). Multiple imputation 15 
analyses performed for missing SGRQ and CAT outcome data showed similar results (Supplementary 16 
Table 1).  Spirometry was repeated only in those attending a face-to-face follow-up interview (6% of 17 
participants); smoking abstinence outcomes were restricted to those reporting abstinence at six 18 
months.  19 
 20 
Process outcomes 21 
Uptake of the intervention was poor. Only 31% (49/157) completed the full intervention, a quarter 22 
(26%, 41/157) partially completed the intervention [HMR only (19/40), Homebase program only 23 
(6/40), HMR and partially completed Homebase program (13/40), partially completed Homebase 24 
program only (3/40)]; and 67 participants (43%) did not receive any part of the intervention.  Reasons 25 
for not receiving the intervention included GP non-referral, participant uncontactable for 26 
appointments, declining exercise, lack of perceived need for HMR, being too busy and declining due 27 
to personal/family circumstances. Of the COPD participants referred and eventually completing the 28 
HMR, 35/81 (43%) were assessed as having suboptimal inhaler technique and 70/81 (86%) 29 
participants were provided demonstration of their inhaler devices by the visiting HMR pharmacist. 30 
There were no significant differences in baseline characteristics between clinics that had at least one 31 
participant completing the full intervention versus clinics that had no participant completing the full 32 
intervention (Supplementary file). Those participants who received the full intervention were more 33 
13 
 
likely to be in a relationship, and had higher SGRQ and CAT scores (i.e. lower quality of life) 1 
compared to those who did not receive the full intervention (Supplementary file).2 
14 
 
 Table 2. SGRQ score differences from baseline to six and 12 months – Intention to treat (ITT) analysis 1 
Outcome Baseline, mean (SD) Within group change at 6 
months, mean (95% CI) 
Between group 
difference at 6 
months, mean  
(95% CI) b 
Within group change at 12 
months, mean (95% CI) 
Between group 
difference at 12 
months, mean 





Usual care Intervention Usual care Intervention 
















2.21 (-2.86, 7.28) 
P = 0.38 
a n=258 at baseline, n=204 at 6 months and n= 185 at 12 months respectively.  2 
b Adjusted for clustering, age, highest education, gross income, current smoking status, and existing COPD  3 
CI=confidence interval; ITT=intention to treat; SD=standard deviation; SGRQ=St George’s Respiratory Questionnaire 4 
 5 
Table 3. CAT, lung function, mMRC grade and HADS score differences from baseline to six and 12 months 6 
Outcome Baseline, mean (SD) Within group change at 6 
months, mean (95% CI) 
Between 
group 
difference at 6 
months, mean  
(95% CI)c 
Within group change at 
12 months, mean (95% 
CI) 
Between group 
difference at 12 
months, mean 




Usual care Intervention Usual care Intervention 
CAT scorea 13.57 
(7.94) 











0.86 (-2.02, 3.74) 
























 Baseline, median [IQR] 6 month follow-up, median [IQR]; 
participants showing improvementh (%) 
12 month follow-up, median [IQR]; 
participants showing improvementh (%) 




Usual care Intervention p-valueg Usual care Intervention p-valueg 
mMRC 
graded 
1 [0-2] 1 [1-2] 1 [1-2]; 
17.0% 











7 [3-9] 6 [3-9] 3 [0-6]; 
69.8% 








4 [2-7] 5 [2-7] 1 [0-4]; 
72.0% 





a n=271 at baseline, n=208 at 6 months and n= 189 at 12 months respectively.  1 
b n=269 at baseline and n=185 at 6 months respectively.  2 
c Adjusted for clustering, age, highest education, gross income, current smoking status, existing COPD 3 
d  n=271 at baseline, n=208 at 6 months and n=190 at 12 months respectively 4 
e n=264 at baseline, n=186 at 6 months and n=170 at 12 months respectively 5 
f n=264 at baseline, n=190 at 6 months and n=172 at 12 months respectively 6 
g p-value of between group differences in proportion of participants showing improvement in grade/score 7 
h follow-up grade/score lower than baseline grade/score indicated improvement 8 
 9 
CAT=COPD Assessment Test; CI=confidence interval; FEV1=forced expiratory volume in 1 second; HADS=Hospital Anxiety and Depression Scale; 10 




Exploratory Per Protocol Analysis (PPA) 1 
An exploratory PPA was performed to assess the effect of the intervention in those who received the 2 
full intervention as intended.  Statistically and clinically significant differences in change in SGRQ 3 
score at six months were observed within the intervention group (5.66; 95%CI 1.91 to 9.42), and 4 
when compared to usual care (adjusted mean difference 5.22; 95%CI 0.19 to 10.25; p=0.042) 5 
(Supplementary Table 2).  The improvement in SGRQ score in the intervention group was more 6 
pronounced and sustained at 12 months; the between group difference was clinically, but not 7 
statistically significant. Multiple imputation analyses confirmed these patterns (Supplementary Table 8 
3).  More than half (23/42, 55%) of the full intervention group participants improved their SGRQ by 9 
the MCID or greater at six months (data not shown).  Although changes in CAT score were more 10 
pronounced in the intervention group (at six and 12 months), between group differences in CAT 11 
scores and FEV1%predicted (at six months only) were not statistically significant.  12 
 13 
DISCUSSION 14 
Our results showed no significant evidence for the effectiveness of an interdisciplinary model of care 15 
in primary care involving smoking cessation support, home medicines review and home-based 16 
pulmonary rehabilitation beyond usual care at improving HRQoL, symptom severity or lung function 17 
in a cohort of patients with predominantly mild COPD.  Nevertheless, an improvement in mean 18 
SGRQ score was evident within the intervention group.  Exploratory analyses of those who received 19 
the intended full intervention showed statistically and clinically significant differences over usual care 20 
at six months, and the benefits within the full intervention group were sustained at 12 months.  21 
However, uptake of the intended intervention components by both GPs and patients was suboptimal.  22 
The effectiveness of integrated disease management programs in COPD is still uncertain.  While a 23 
recent Cochrane review showed positive effects of these interventions on HRQoL,7  there was 24 
considerable heterogeneity between the included studies, mainly due to differences in the healthcare 25 
systems where these trials took place.43 Our interdisciplinary model coordinated by the patient’s GP 26 
could not achieve fully integrated care due to a range of patient-, health professional- and health 27 
system-related factors. Our findings concur with recent studies of primary care-based COPD 28 
management programs targeting those with relatively mild disease in Australia, the Netherlands, and 29 
Switzerland, which showed no additional benefit of disease management and health professional 30 
partnership programs on HRQoL over usual care.7-9  31 
More specifically, our results are similar to the primary-care based COPD management program of 32 
Kruis et al conducted in the Netherlands, however there were some key differences in the intervention 33 
design. Kruis et al offered an intervention consisting primarily of intensive training provided to GPs, 34 
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nurses and physiotherapists on how to implement integrated disease management in practice, whereas 1 
RADICALS had a GP-coordinated interdisciplinary intervention where every GP and participant in 2 
the intervention arm was offered the intervention comprising smoking cessation support, HMR and 3 
home-based pulmonary rehabilitation. Our study also included a case-finding component for 4 
optimising the diagnosis of COPD in primary care. The study population comprised many newly 5 
diagnosed patients who had mild disease.13 Low baseline SGRQ scores, low mMRC scores, and mild 6 
disease based on FEV1 %predicted28 may explain the small effect observed. A ‘floor effect’ is a 7 
possible explanation for the minimal changes observed in SGRQ, other quality of life scores and 8 
dyspnoea.6, 8, 9 It is likely that COPD was not a priority for either GPs or participants for discussions 9 
during consultations and for subsequent interventions if patients had only mild symptoms, explaining 10 
the modest uptake of the interventions in this group.  11 
Although the change in SGRQ in our trial was minimal, the magnitude of change in SGRQ in the 12 
intervention arm at six and 12 months is on par with a recent large clinical trial of combination 13 
pharmacotherapies in patients with moderate to very severe COPD.44 The interventions delivered in 14 
our study model are services or resources that are readily available and could be complementary to 15 
pharmacological treatments for COPD, if implemented early and more widely. This model could 16 
potentially be more effective in primary care by targeting those with symptoms and with better 17 
intervention fidelity.  18 
Participation in pulmonary rehabilitation has been shown to improve HRQoL in patients with 19 
COPD.20  The HomeBase program in the RADICALS model is equivalent to centre-based pulmonary 20 
rehabilitation at improving HRQoL for patients with moderate to severe disease.22  However, the 21 
effectiveness of pulmonary rehabilitation programs for mild COPD is still uncertain.45 The majority of 22 
our trial population had low levels of activity limitation (most participants self-reported low mMRC 23 
grades), and therefore may not have recognised the need for the intervention.  24 
The roles of pharmacists in COPD management and positive effects of interventions on medication- 25 
adherence and inhaler technique have been previously shown.18 Such advice was routinely provided to 26 
participants by the pharmacist during the HMR.  Due to the large number of practices and GPs 27 
involved, it was not possible to ensure that pharmacist recommendations were implemented by GPs, 28 
which may have diminished the effect. 29 
 30 
Strengths and limitations 31 
The key strength of this study was the assessment of real-world effectiveness of an interdisciplinary 32 
model of care comprising resources and services readily accessible in primary care.  Multiple clinics 33 
and GPs were recruited into the study; clinics varied in size, availability of respiratory services, and 34 
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socio-economic status of the clientele, increasing the generalisability of our findings.  Cluster 1 
randomisation minimised the risk of contamination associated with the same practice staff treating 2 
participants from different trial arms.  Although there was the potential for Hawthorne effect in this 3 
open-label study (participants and health professionals were not blinded), outcome assessments were 4 
performed by RAs blinded to group allocation.  5 
Practice and participant recruitment was challenging.  The numbers of clinics and participants in the 6 
two arms were unbalanced and not all clinics contributed to the COPD cohort.  Attrition rates were 7 
slightly higher than originally anticipated, also contributing to the small effects observed; those who 8 
completed all follow-ups may not be representative of the wider COPD population, especially those 9 
with mild or no symptoms.  Greater variability in SGRQ scores was seen due to recruitment of 10 
subjects with any severity of COPD.  We did not assess changes in pharmacological or non-11 
pharmacological COPD management in usual care participants. We also could not tell whether 12 
participants undertook traditional hospital outpatient pulmonary or received HMR (both existing 13 
services in Australia) during the study through other sources.  Trial effects, dissemination of COPD-X 14 
and smoking cessation guidelines, lung function testing and provision of spirometry results to GPs in 15 
the usual care arm, might have prompted changes in COPD management in these participants, which 16 
would not have otherwise occurred. We did not assess changes in participant behaviours such as 17 
adherence to medication, inhaler technique and adherence to home exercises.  18 
A key limitation is the low uptake of the intervention components. Due to logistical and resource 19 
limitations, we did not organise interviews with patients, practice managers or GPs to obtain more 20 
information on process outcomes and detailed reasons for the low uptake. Although per-protocol 21 
analyses revealed statistically significant changes in SGRQ at six months, this standalone positive 22 
outcome should be interpreted with caution. Most importantly, poor uptake of the intervention does 23 
not allow us to interpret whether the negative findings were resultant from being unable to deliver the 24 
intervention or from intervention failure. 25 
 26 
Practice implications and future research 27 
Challenges in implementation and slow uptake of the non-pharmacological interventions offered 28 
within this pragmatic trial are important lessons for future primary care studies.  There were delays in 29 
delivering the multi-component intervention due to the multiple steps involved e.g. spirometry results 30 
review (with or without expert input in interpretation and diagnosis), organising of patient visits to 31 
discuss results, eventual referral to HMR and/or HomeBase by GP following patient consent, and GP 32 
follow-up visit to implement pharmacist HMR report recommendations.  Efforts made to educate GPs 33 
and participants on the potential benefits of HMR and HomeBase did not necessarily translate to 34 
referral and/or uptake.  Although the clinic management agreed to participate in the trial, not all GPs 35 
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practising within each clinic actively supported trial implementation.  Limited resources for delivering 1 
the intervention at the clinic level due to competing demands for GPs’ time and inadequate 2 
remuneration for delivering the service might have been barriers.  Lack of implementation fidelity can 3 
make interventions appear to be ineffective.46 4 
Future studies should factor in the real-world challenges of recruitment, time considerations, and 5 
diagnostic and referral processes in the primary care setting.  Specific training on integrated disease 6 
management concepts provided to health professionals involved should be considered and may 7 
potentially increase delivery of integrated care in practice. 8 
Where possible, a phased approach to intervention development with preliminary testing (including 9 
collecting information on reasons for non-referral to intervention components) should be conducted to 10 
inform feasibility and level of uptake of interventions by GPs and participants. Engagement of 11 
individual GPs, a more proactive and streamlined intervention referral process, detailed explanation of 12 
the disease and its effects to patients, and the potential benefits of non-pharmacological interventions 13 
such as HomeBase and HMRs may improve participant interest and intervention uptake.  14 
In primary care, uptake of and adherence to healthy behaviours (smoking cessation, increased 15 
physical activity) and self-management skills (optimal use of inhaled medications, and early 16 
recognition and treatment of worsening of symptoms) may be better predictors of longer-term 17 
outcomes in patients with mild disease. Patient needs, preferences and personal goals should be 18 
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Supplementary Table 1. Quality of life, symptoms and respiratory function at baseline, six and 12 months – ITT with Multiple imputation 
Outcome Within group change at 6 
months, mean (95% CI) 
Between group 
difference  at 6 
months, mean  
(95% CI) b 
Within group change at 12 
months, mean (95% CI) 
Between group 
difference  at 12 
months, mean 
(95% CI) b 
Usual care Intervention Usual care Intervention 












1.94 (-2.92, 6.80) 
P = 0.41 











0.64 (-1.99, 3.27) 









 (-0.80, 2.36) 
1.12 
(-1.84, 4.08) 








a Participants with baseline outcome measure included in multiple imputation analysis 
b Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering 
CAT=COPD Assessment Test; CI=Confidence Interval; FEV1; Forced Expiratory Volume in 1 second; ITT=intention to treat; SGRQ=St George’s 
Respiratory Questionnaire;  
Supplementary table 2. Quality of life, symptoms and respiratory function at six and 12 months – Per protocol analysis (PPA) 
Outcome Within group change at 6 
months, mean (95% CI) 
Between group 
difference  at 6 
months, mean  
(95% CI) d 
Within group change at 12 
months, mean (95% CI) 
Between group 
difference at 12 





















4.02 (-2.19, 10.23) 
P = 0.20 











1.42 (-1.87, 4.71) 








 (-1.68, 4.37) 
2.03 
(-1.73, 5.79) 








a n=157 at baseline, n=137 at 6 months and n= 120 at 12 months respectively.  
b n=163 at baseline, n=140 at 6 months and n= 121 at 12 months respectively.  
c n=162 at baseline and n=125 at 6 months respectively.  
d Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering 
CAT=COPD Assessment Test; CI=Confidence Interval; FEV1=Forced Expiratory Volume in 1 second; PPA=Per Protocol Analysis; SGRQ=St George’s 
Respiratory Questionnaire 
 
Supplementary table 3. Quality of life, symptoms and respiratory function at six and 12 months – PPA with Multiple Imputation 
Outcome Within group change at 6 
months, mean (95% CI) 
Between group 
difference  at 6 
months, mean  
(95% CI) b 
Within group change at 12 
months, mean (95% CI) 
Between group 
difference  at 12 
months, mean 






















P = 0.21 





















 (-1.27, 4.64) 
2.29 
(-1.63, 6.21) 








a Participants with baseline outcome measure included in multiple imputation analysis 
b Adjusted for age, highest education, gross income, current smoking status, existing COPD and clustering 
CAT=COPD Assessment Test; CI=Confidence Interval; FEV1=Forced Expiratory Volume in 1 second; PPA=Per Protocol Analysis; SGRQ=St George’s 
Respiratory Questionnaire 
1. Comparing baseline characteristics of intervention clinics whereby at least one patient received the full intervention vs characteristics
of intervention clinics where no patient received the full intervention
Characteristic 
Intervention clinics 





with no participant 
who completed full 
intervention (n=6) p-value
Type of practice 1.00 
Single GP practice 2 (12.5%) 1 (16.7%) 
Group GP practice/community health 
centre/interdisciplinary practice 12 (75.0%) 5 (83.3%) 
Community health centre 1 (6.3%) 0 (0.0%) 
Interdisciplinary practice 1 (6.3%) 0 (0.0%) 
Number of GPs, median [IQR] 8 [4.5-12.5] 4 [4-5] 0.053 
Number of patients on database, median 
[IQR] 9657 [7843-43289] 4900 [1182-12160] 0.15 
Spirometer available 5 (31.3%) 2 (33.3%) 1.00 
Staff training in Smoking cessation in 
past two years  2 (12.5%) 1 (16.7%) 1.00 
Staff training in COPD management in 
past two years  3 (18.9%) 0 (0%) 0.53 
Staff training in Spirometry in past two 
years  5 (31.3%) 1 (16.7%) 0.63 
2. Comparing baseline characteristics of those who completed the trial (i.e. was able to be followed up at 12 months) vs those who 





Did not complete trial 
(n=82) p-valuee 
Age, mean (SD) 66.0 (10.1) 61.2 (11.6) 0.008 
Gender, male 116 (61.1%) 51 (62.2%) 0.87 
Born in Australiaa 144 (75.8%) 56 (70.9%) 0.41 
Mainly speak English at home 188 (98.9%) 79 (96.3%) 0.16 
Educationa   0.16 
   No formal schooling/up to primary 
school/primary school 9 (4.7%) 9 (11.4%)  
   High school 94 (49.5%) 37 (46.8%)  
   Technical/further education 50 (26.3%) 23 (29.1%)  
   University education/postgraduate 37 (19.5%) 10 (12.7%)  
Employment statusa   0.54 
   Employed-full/part-time/casual 50 (26.7%) 26 (31.7%)  
   Retired/pensioner 106 (56.7%) 46 (56.1%)  
   Unemployed/home duties/student/unable 
to work/disabled 31 (16.6%) 10 (12.2%)  
Marital statusa   0.002 
   Married/de-facto/engaged 100 (52.6%) 22 (27.8%)  
   Separated/divorced/widowed/never 
married/single 90 (47.4%) 56 (70.9%)  
   Undisclosed 0 (0.0%) 1 (1.3%)  
Current living arrangementsa   0.047 
   With family/friends/spouse/partner 130 (68.4%) 43 (54.4%)  






























aData unavailable for n=3 bData unavailable for n=11 cData unavailable for n=14 dData unavailable for n=8 eAll p values are adjusted for clustering effect 
   Shared accommodation/community 
housing/refuge accommodation/residential 
facility/residential aged care facility 4 (2.1%) 5 (6.3%)  
Average annual household incomeb    0.17 
   <AUD $30,000 82 (44.3%) 37 (48.7%)  
   AUD $30,000-$59,999 42 (22.7%) 15 (19.7%)  
   AUD $60,000 or more 41 (22.2%) 8 (10.5%)  
   Did not want to disclose 20 (10.8%) 16 (21.1%)  
Previously managed as having COPD 88 (46.3%) 42 (51.2%) 0.41 
Currently smoking 112 (58.9%) 54 (65.9%) 0.32 
Heaviness of Smoking Index score   0.97 
   Low nicotine dependence (score 0-2) 31 (27.9%) 14 (27.5%)  
   Moderate nicotine dependence (score 3-4) 62 (55.9%) 28 (54.9%)  
   High nicotine dependence (score 5-6) 18 (16.2%) 9 (17.6%)  
Post-bronchodilator FEV1 %predicted, 
mean (SD) a 71.9 (19.7) 64.8 (19.8) 0.017 
Post-bronchodilator FEV1 / FVC, mean 
(SD)a 0.58 (0.11) 0.55 (0.13) 0.11 
Disease severitya    0.21 
   Mild 140 (74.1%) 50 (62.5%)  
   Moderate 35 (18.5%) 21 (26.3%)  
   Severe 14 (7.4%) 9 (11.3%)  
SGRQ score, mean (SD)c 31.6 (17.3) 33.4 (20.0) 0.45 
CAT score, mean (SD) 12.8 (7.4) 14.2 (8.3) 0.15 
HADS anxiety score, median [IQR]d 5 [3-8] 7 [3-10] 0.31 
HADS depression score, median [IQR]d 4 [2-7] 5 [3-7] 0.38 
mMRC grade, median [IQR] 1 [0-2] 1 [0-2] 0.72 
3. Comparing baseline characteristics between full intervention group in intervention arm vs those who did not receive full intervention 





Did not receive full 
intervention (n=108) p-valuee 
Age, mean (SD) 67.7 (10.1) 66.2 (11.2) 0.43 
Gender, male 27 (55.1%) 68 (63.0%) 0.34 
Born in Australiaa 38 (77.6%) 76 (72.4%) 0.45 
Mainly speak English at home 49 (100.0%) 105 (97.2%) 0.65 
Educationa   0.17 
   No formal schooling/up to primary 
school/primary school 3 (6.1%) 11 (10.5%)  
   High school 19 (38.8%) 49 (46.7%)  
   Technical/further education 16 (32.7%) 35 (33.3%)  
   University education/postgraduate 11 (22.5%) 10 (9.5%)  
Employment status   0.68 
   Employed-full/part-time/casual 18 (36.7%) 33 (30.6%)  
   Retired/pensioner 25 (51.0%) 59 (54.6%)  
   Unemployed/home duties/student/unable 
to work/disabled 6 (12.2%) 16 (14.8%)  
Marital statusa   0.02 
   Married/de-facto/engaged 28 (57.1%) 41 (39.1%)  
   Separated/divorced/widowed/never 
married/single 21 (42.9%) 64 (60.9%)  
Current living arrangementsa   0.78 
   With family/friends/spouse/partner 33 (67.4%) 64 (61.0%)  






























aData unavailable for n=3 bData unavailable for n=8 c Data unavailable for n=2 dData unavailable for n=6 eAll p values are adjusted for clustering effect 
   Shared accommodation/community 
housing/refuge accommodation/residential 
facility/residential aged care facility 0 (0.0%) 6 (5.7%)  
Average annual household incomeb   0.78 
   <AUD $30,000 22 (44.9%) 52 (52.0%)  
   AUD $30,000-$59,999 12 (24.5%) 20 (20.0%)  
   AUD $60,000 or more 10 (20.4%) 21 (21.0%)  
   Did not want to disclose 5 (10.2%) 7 (7.0%)  
Previously managed as having COPD 29 (59.2%) 45 (41.7%) 0.06 
Currently smoking 22 (44.9%)  62 (57.4%) 0.15 
Heaviness of Smoking Index score 
(current smokers only)   0.98 
   Low nicotine dependence (score 0-2) 5 (23.8%) 16 (27.1%)  
   Moderate nicotine dependence (score 3-4) 12 (57.1%) 32 (54.2%)  
   High nicotine dependence (score 5-6) 4 (19.1%) 11 (18.6%)  
Post-bronchodilator FEV1 %predicted, 
mean (SD) c 68.3(20.6) 69.3 (20.5) 0.75 
Post-bronchodilator FEV1 / FVC, mean 
(SD) c 0.57 (0.14) 0.57 (0.12) 0.93 
Disease severity c   0.49 
   Mild 32 (66.7%) 76 (71.0%)  
   Moderate 9 (18.8%) 21 (19.6%)  
   Severe 7 (14.6%) 10 (9.4%)  
SGRQ score, mean (SD)b 38.4 (17.8) 29.9 (17.4) 0.004 
CAT score, mean (SD) 15.4 (7.7) 11.8 (7.3) 0.002 
HADS anxiety scoreb, median [IQR] 5 [3-9] 6 [3-9] 0.59 
HADS depression scored, median [IQR] 5 [3-7] 5 [2-7] 0.57 
mMRC grade, median [IQR] 1 [1-2] 1 [0-2] 0.10 
 
4. Comparing baseline respiratory medications in the intervention group only between those who completed HMR vs those who did not 
complete HMR 
 
Medication data was missing for 1 participant 
aData are presented as number(percentage) or median (inter-quartile range) 




5. Comparing baseline motivation to quit scores across groups at baseline (for current smokers only) 
 
Characteristic (median [IQR]) Usual care (n=82) Intervention (n=84) p-valueb 
Motivation to quit (current smokers 
only)a 5 [3-8] 6 [3-8] 
0.26 
a missing data for 3 participants bAll p values are adjusted for clustering effect 
Characteristica  
Did not complete 
HMR (n=76) 
Completed HMR 
(n=81) p-value b 
SABA 22 (29.0%) 34 (42.5%) 0.019 
SAMA 2 (2.6%) 3 (3.8%) 0.72 
ICS alone 3 (4.0%) 2 (2.5%) 0.61 
ICS/LABA alone 11 (14.5%) 8 (10.0%) 0.22 
LABA/LAMA alone 0 (0%) 2 (2.5%) 0.52 
LABA alone 0 (0.0%) 0 (0.0%) --- 
LAMA alone 11 (14.5%) 18 (22.5%) 0.20 
Triple therapy (ICS & LABA & LAMA) 15 (19.7%) 25 (31.3%) 0.06 
Number of non-respiratory medications 3 [2-6] 5 [2-8] 0.12 
 Clinics randomised (N=41)* 
Clinics allocated to usual care group (N=20) Clinics allocated to intervention group (N=21) 
Clinics contributed to recruitment of participants 
(N=18) 
Participants consented, and completed baseline 
data collection and case-finding (n=432) 
 
Clinics contributed to recruitment of participants 
(N=21) 
Participants consented, and completed baseline data 
collection and case-finding (n=618)  
 
 Clinics from which COPD participants were 
identified (N=16) 
Participants with COPD (n=115) 
 
Clinics from which COPD participants were identified 
(N=19) 
Participants with COPD (n=157)  
 
Referred for HMR (n=105) 
Referred for pulmonary rehabilitation (n=107) 
 
Full intervention (HMR and ≥6 sessions of pulmonary 
rehabilitation program) (n=49, 31%) 
Partial intervention (n=41, 26%) 
   HMR only (n=19) 
   ≥6 sessions of pulmonary rehabilitation program only (n=6) 
   HMR and <6 sessions of pulmonary rehabilitation (n=13) 
   <6 sessions of pulmonary rehabilitation only (n=3) 
No intervention (n=67, 43%) 
 
Included in ITT and multiple imputation analyses (n=157) 
Included in per protocol analyses (n=49) 
Clinics withdrew 
(N=2) 
Changes to clinic 
staff (N=1), 
Changes in ability 
to accommodate 
study (N=1) 
Clinics did not 
have participants 
with COPD (N=2) 
Included in ITT and multiple imputation analyses (n=115) 
Included in per protocol analyses (n=115) 




(n=4); Moved to nursing 
home (n=1) 
Clinics did not have 
participants with COPD 
(N=2) 
Not referred for HMR by GP 
(n=52); Not referred for 
pulmonary rehabilitation by 
GP (n=50) 
 Did not complete HMR 
(n=24) 
Declined/withdrew (n=17); 
Uncontactable for making 
appointments (n=7) 
Did not start pulmonary 
rehabilitation (n=36) 
Declined/withdrew (n=27); 
Uncontactable for making 
appointments (n=9) 




(n=15); Deceased (n=2) 
 
 
Lost to follow-up at 12 
months (n=38)†  
Not contactable/unavailable 
(n=29); Declined/withdrew 
(n=7); Moved (n=1); 
Deceased (n=1) 
*Total of 43 clinics; two clinics belonged to the same consortium where GPs and clinic staff worked across clinics – these clinics were collectively 
treated as one entity and allocated to the same arm as the clinic initially recruited 
†Some participants were available at 6 month follow-up but not available at 12 month follow-up, and vice versa 
COPD = chronic obstructive pulmonary disease; GP = general practitioner; HMR = home medicines review; ITT = intention-to-treat 
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